Former FDA Acting Commissioner Friedman
Executive SummaryPharmaceutical Research & Manufacturers of America Chief Medical Officer for Biomedical Preparedness Michael Friedman, MD, is named CEO of City of Hope cancer research and treatment center (Los Angeles), effective May 1. PhRMA's biomedical preparedness team now reports to Chief Scientist-Biomedical Preparedness and Lilly VP-Scientific Affairs Gail Cassell, PhD. Friedman was also serving as Pharmacia's senior VP-medical public policy. The firm recently completed its merger with Pfizer. Friedman was FDA deputy commissioner for operations from 1995 to 1999 and headed the agency as acting commissioner after the departure of Commissioner Kessler in 1997...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.